Insider · CIK 0001173970
R Janet Whitmore
Files at SLSN (SOLESENCE, INC.). First filing Nov 5, 2024, latest Dec 30, 2025.
In brief
R Janet Whitmore files SEC Form 4 as director at SLSN (SOLESENCE, INC.). Since Nov 5, 2024, R Janet Whitmore has reported 3 open-market buys worth $106k and 0 open-market sells worth $0, the latest filed on Dec 30, 2025.
A track record needs three past buys with six months of prices behind them; R Janet Whitmore has 0, so none is measured yet.
The newest scored trade: bought $4,787 of SLSN on Dec 24, 2025, filed Dec 30, 2025, scored 15 (weak). In the last 12 months: 2 buys worth $68k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SLSN: SOLESENCE, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | SLSNbuy SOLESENCE, INC. | $4,787 2,500 shares | +0% | - | |
| 23Weak | SLSNbuy SOLESENCE, INC. | $63k 35,056 shares | +2% | - | |
| 21Weak | SLSNbuy SOLESENCE, INC. | $38k 45,333 shares | +2% | - |
Transactions
Every row this insider has filed, 27 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 24, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +1,500 | $1.91 | $2,865 | 2,085,698 | Dec 30, 2025 |
| Dec 24, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +1,000 | $1.92 | $1,922 | 2,086,698 | Dec 30, 2025 |
| Nov 14, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +19,789 | $1.73 | $34k | 2,068,931 | Dec 11, 2025 |
| Nov 17, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +5,000 | $1.87 | $9,350 | 2,073,931 | Dec 11, 2025 |
| Nov 18, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +267 | $1.83 | $489 | 2,074,198 | Dec 11, 2025 |
| Nov 19, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +5,000 | $1.95 | $9,750 | 2,079,198 | Dec 11, 2025 |
| Nov 19, 2025 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +5,000 | $1.89 | $9,450 | 2,084,198 | Dec 11, 2025 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $0.90 | $1,800 | 2,005,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $1.05 | $2,100 | 2,007,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $1.18 | $2,360 | 2,009,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $0.84 | $1,680 | 2,011,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $1.10 | $2,200 | 2,013,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +2,000 | $0.99 | $1,980 | 2,015,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +10,000 | $0.68 | $6,800 | 2,025,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +10,000 | $0.82 | $8,200 | 2,035,809 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +6,667 | $0.45 | $3,000 | 2,042,476 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | POpen-market purchase Common Stock | +6,666 | $1.17 | $7,766 | 2,049,142 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $0.90 | $1,800 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $1.05 | $2,100 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $1.18 | $2,360 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $0.84 | $1,680 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $1.10 | $2,200 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -2,000 | $0.99 | $1,980 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -10,000 | $0.68 | $6,800 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -10,000 | $0.82 | $8,200 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -6,667 | $0.45 | $3,000 | 0 | Nov 5, 2024 |
| Oct 29, 2024 | SLSN SOLESENCE, INC. | MOption exercise Common Stock (Right to Buy)derivative | -20,000 | $1.17 | $23k | 13,334 | Nov 5, 2024 |
Questions about R Janet Whitmore
Answered from the filings on this page, as of the latest one.
Is R Janet Whitmore buying or selling?
In the last 12 months R Janet Whitmore reported 2 open-market buys worth $68k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $4,787 of SLSN on Dec 24, 2025. Grants, option exercises and tax withholding are not counted.
How did R Janet Whitmore's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and R Janet Whitmore has 0.
Where does R Janet Whitmore file Form 4?
R Janet Whitmore has filed Form 4 at SLSN (SOLESENCE, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.